ash 2017 abstracts

ash 2017 abstracts

ash 2017 abstracts

Abstracts submitted for oral and poster presentations at the ASH annual meeting represent important, novel research in the field and are considered the best of the thousands of abstracts submitted. Typically, more than 5,000 scientific abstracts are submitted each year and more than 3,000 abstracts are accepted for oral and poster presentations through an extensive peer review process.
ASH is moving forward with preparations for the 62nd ASH Annual Meeting and Exposition December 5-8, 2020, in San Diego, California. The Society is also preparing for various contingencies should the live, face-to-face conference not be possible based upon the safety and health of our speakers, attendees, and staff. ASH will continue to monitor the situation carefully and provide updates on the ASH Annual Meeting webpage.

BOSTON, Nov. 01, 2017 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, today announced that five abstracts highlighting data from the Company’s adoptive cell-based therapeutic programs have been accepted for presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition, December 9-12, in Atlanta.
Data from ongoing clinical and preclinical studies will be highlighted at ASH including research, conducted with collaborators at The University of Texas MD Anderson Cancer Center and Intrexon Corporation (NYSE:XON), that further validates the Company’s Sleeping Beauty (SB) platform in chimeric antigen receptor (CAR) modified T cell therapy and demonstrates the potential for very rapid T-cell production (

Thanks for your feedback, this will help us improve our content for you!
The American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA, showcased the most cutting-edge data in the field of hematology by research groups from all over the world. Speaking from the conference, Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, gives an overview of the most anticipated data to be presented. These include details of the ECHELON-1 trial (NCT01712490), the efficacy of acalabrutinib in relapsed mantle cell lymphoma, follow up data on the LyMa trial (NCT00921414), and an evaluation of current PET scanning practices.

References:

http://ir.ziopharm.com/news-releases/news-release-details/ziopharm-announces-five-abstracts-accepted-presentation-2017
http://www.vjhemonc.com/video/n4cjes9_qek-key-abstracts-being-presented-at-ash-2017/
http://www.escardio.org/Congresses-&-Events/ESC-Congress/Call-for-Science/Abstracts

Leave a Reply